POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
February 24 2021 - 8:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery, is
excited to announce today that it has completed key data generation
milestones in its retrospective study in collaboration with
UPMC-Magee Women Hospital, to build AI-driven models of ovarian
cancer. Comprehensive genomic and transcriptomic sequencing of
patient samples is now complete and patient outcome data has been
obtained from UPMC-Magee. These data will now be used to drive both
our AI-models of ovarian cancer as well as our internal ovarian
cancer drug re-purposing project.
“We are excited to have reached these key sequencing and data
generation milestones as these data are the foundation of our
AI-driven predictive models of patient outcome, which will further
extend our clinical offering and help oncologists individualize
patient therapy. In addition, these data will play an important
role in our internal drug repurposing project for ovarian cancer,
by providing additional information to help drive our AI-driven
patient-centric platform, PeDAL™," explained Dr Schwartz, CEO of
POAI.
“The successful generation of high quality genomic and
transcriptomic data from archived materials at Helomics, together
with the gathering of historical outcome data from our collaborator
UPMC-Magee, demonstrates that we can leverage Helomics’ unique
asset and deliver significant value. Furthermore, this project is a
template we can use to partner with other healthcare institutions
and expand our AI-driven clinical models to other cancers,” added
Dr. Schwartz.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Skyline, Helomics and Soluble Biotech), which contain
four subsidiaries: Helomics, TumorGenesis, Skyline Medical and
Soluble Biotech.
Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. TumorGenesis Inc.
specializes in media that help cancer cells grow and retain their
DNA/RNA and proteomic signatures, providing researchers with a tool
to expand and study cancer cell types found in tumors of the blood
and organ systems of all mammals, including humans. Skyline Medical
markets its patented and FDA cleared STREAMWAY System, which
automates the collection, measurement and disposal of waste fluid,
including blood, irrigation fluid and others, within a medical
facility, through both domestic and international divisions.
Soluble Biotech is a provider of soluble and stable formulations
for proteins including vaccines, antibodies, large and small
proteins and protein complexes. For more information, please
visit www.predictive-oncology.com.
Forward-looking Statements
Certain of the matters discussed in this press release contain
forward-looking statements that involve material risks to and
uncertainties in the Company’s business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include:
market and other conditions, the completion of the private
placement, the satisfaction of customary closing conditions related
to the private placement and the intended use of net proceeds from
the private placement, a variety of other risks and uncertainties
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Landon CapitalKeith Pinder(404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024